mission

Vision & Mission

Marvi Pharmaceuticals aspires to be a leading force in the healthcare industry both locally and regionally by providing high quality new and improved medicines and services. We are dedicated to make a difference in people’s lives by understanding, fulfilling and satisfying their unmet medical needs. We aim to provide innovative, high end products and services that save and improve lives and satisfy customer needs, a place where our employees realize their true potential and create stakeholder value. Our organization is committed to achieve its goals consistently through a performance-driven culture built around Ethics, Trust, Fairness and Responsibility.

News & Events

Monthly News Roundup - August 2017

Posted: August 2017

Kymriah from Novartis Approved as First U.S. CAR-T Cell Therapy

History was made this month as the U.S. Food and Drug Administration (FDA) approved the first U.S. cell-based gene therapy known collectively as chimeric antigen receptor (CAR) T-cell therapy. Kymriah (tisagenlecleucel or CTL019) from Novartis was approved for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. Kymriah is a genetically-modified T-cell immunotherapy customized for each patient using their own T-cells, a type of white blood. In one study of 63 patients with relapsed or refractory B-cell precursor ALL, the overall remission rate within three months of treatment was 83 percent. Kymriah contains a boxed warning for cytokine release syndrome (CRS) and neurotoxicity.

Cyltezo: Boehringer Ingelheim Wins Approval on Their First Biosimilar

Cyltezo (adalimumab-adbm) is an anti-TNF-α monoclonal antibody biosimilar to Humira, now approved in a pre-filled syringe for the treatment of various inflammatory diseases including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis. It can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs. (DMARDs). No FDA Advisory committee convened for discussion of Cyltezo; it was approved based on a comprehensive data package comprised of analytical, pharmacological, non-clinical and clinical development studies. The other biosimilar for adalimumab is Amgen’s Amjevita (adalimumab-atto).

Vabomere Clears FDA for Complicated Urinary Tract Infections

The FDA has approved intravenous Vabomere (meropenem and vaborbactam) for adults with complicated urinary tract infections (cUTI), including pyelonephritis caused by specific bacteria. Vabomere contains meropenem, an antibacterial, and vaborbactam, a β-lactamase inhibitor which inhibits certain types of resistance mechanisms used by bacteria. In studies with 545 adults with cUTI, including those with pyelonephritis, roughly 98% of patients treated with Vabomere had a cure or improvement in symptoms and a negative urine culture test. The most common adverse reactions in patients taking Vabomere were headache, infusion site reactions and diarrhea, among others.

Pfizer's Besponsa FDA-Approved for Advanced Forms of ALL

Life expectancy after a return of acute lymphoblastic leukemia is low and treatment options are few. In response, the FDA has approved Pfizer's Besponsa (inotuzumab ozogamicin), a CD22 monoclonal antibody and calicheamicin cytotoxic agent conjugate for relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults. Besponsa binds to B-cell ALL cancer cells that express the CD22 antigen blocking the growth of cancerous cells. In studies, 35.8% of those who received Besponsa experienced complete response (CR) for a median 8 months; of the patients who received alternative chemotherapy, 17.4 percent experienced CR for a median 4.9 months.

Mavyret Cleared as First 8-Week Hepatitis C Treatment for All Genotypes

The FDA has approved AbbVie's oral Mavyret (glecaprevir and pibrentasvir), the first 8-week treatment for all chronic hepatitis C virus (HCV) genotypes (1-6) in adult patients without cirrhosis (liver disease) and without previous treatments. Standard treatment length for HCV was previously 12 weeks or more. Glecaprevir inhibits NS3/4A protease and pibrentasvir inhibits NS5A. Mavyret is approved for two patient populations: either chronic HCV genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A), or adult patients with HCV genotype 1 infection, previously treated with an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both. Studies demonstrated that 92 to 100 percent of patients had no virus detected in the blood 12 weeks after finishing treatment, suggesting a cure. The most commonly reported adverse reactions (> 10%) are headache and fatigue.

Quality

Quality Assurance:

For us Quality is not an Act but a habit. Today we have more than 41 products in Marvi Pharmaceuticals and its Nutraceuticals Division Marvi Health Sciences. We have always focused on improving the health of community by offering safe efficacious and quality products. We have progressed firmly to deliver the products to our customer from such units which are designed as per WHO - GMP and other international regulatory standards. Presently we have ISO 9000 approved products.

Quality Management System:

we at Marvi Pharmaceuticals have certain quality parameters designed as per the requirement of ISO 9001:2008.and is also ISO 9001:2008 certified company. Our quality management system (QMS) covers all the sections of manufacturing to its distribution.this system defines all the criteria required for the effective operation and control of the processes and their documentation Our quality policy:the management and employees of Marvi Pharmaceuticals are fully committed to meet and satisfy the customer requirements and to provide satisfactory customer service through continuous improvement in the services. To achieve customer satisfaction by putting maximum range of quality products by taking feedback from all associates. To achieve international level of standard in pharma product selling by adopting best quality in products and distribution. For this here at Marvi Pharmaceuticals everything is planned starting from the purchase to the distribution .Our Documentation work is well planned and we have maintained all the records. Which include approval, issue of approval, review, re-approval of all the products, their test reports. This procedure of maintaining documents is as per the clause of ISO 9001:2008. In order to check whether the all systems are functioning properly we have the procedure of conducting internal audits which is as per the clause of ISO 9001:2008. And there is a system managed by top authorities which is responsible for planning, controlling, assigning work, sale targets to the associated persons

Customer Focused:

From leadership down through our entire organization, we measure ourselves and our actions through the lens of our customers and patients. We look to build strong relationships with our customers and then deliver on quality products and service.

Innovation:

A continued emphasis on innovation remains an essential business strategy – searching out new ways to do things and continuously identifying opportunities to design, develop and advance creative, ethical solutions that are timely and effective.

Efficiency:

Our focus and execution enable Valeant to drive productivity throughout the organization, leaving no stone unturned in identifying where we can make improvements and deliver value. We address the challenges inherent with a changing market quickly and never compromise on quality…………………………………………………………………………………

People:

Our employees come to work each day focused on improving peoples’ lives through our healthcare products. They are essential to the success of the organization. We strive to build and retain a strong team by recognizing and rewarding excellence and creating development opportunities. High-performing individuals are critical as they provide a foundation for future success.

Marvi Pharmaceuticals Ltd.

Head Office

Plot # 70 Sector 24, Korangi Industrial Area Karachi Pakistan,

Phone:

+92-21-35055386/87

Fax No:

+92-21-35055388

Email:

marvipharmaceuticals@gmail.com

Website : www.marvipharmaceuticals.com

Check1

Check2

Check3